2023-04-17 10:48:07 ET
The U.S. Supreme Court on Monday declined to hear a case filed by Sanofi ( NASDAQ: SNY ) to revive an antitrust lawsuit that charged Viatris ( NASDAQ: VTRS ) of illegally monopolizing the U.S. market for the Epinephrine auto-injectors.
The justices turned down Sanofi's’ ( SNY ) appeal to review a lower court ruling that favored Mylan, which joined Pfizer’s ( PFE ) UpJohn spinoff in 2020 to form Viatris ( VTRS ).
Sanofi ( SNY ) has long maintained that the generic drugmaker blocked competition to its Epinephrine auto-injector, Auvi-Q, using anticompetitive practices to market the latter’s rival device EpiPen.
Epinephrine auto-injectors such as EpiPen and Auvi-Q are used to treat serious and potentially fatal allergic reactions to food, medications, and other agents.
The legal fight began in 2017 when Sanofi ( SNY ) sued Mylan for violating antitrust laws by handing rebates to pharmacy benefit managers (PBMs) to gain exclusivity for its auto-injector.
A federal judge in Kansas City, Kansas, turned down the claims ruling in favor of Mylan, and the Denver-based 10th U.S. Circuit Court of Appeals agreed with the verdict last July.
Read: Seeking Alpha analyst Gen Alpha issued a Buy rating on Viatris ( VTRS ) after the company met its expectations for 2022.
For further details see:
Supreme Court turns down Sanofi bid to revive EpiPen lawsuit against Viatris